SADHART

AcronymDefinition
SADHARTSertaline AntiDepressant Heart Attack Randomized Trial
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Demonstrated by the SADHART trial described above, sertraline is relatively safe and efficacious in depressed patients with ischemic heart disease.[sup][10] It has also been demonstrated in our study that SSRIs have generally reduced the morbidity and mortality of depression with comorbid heart disease: pretreatment with sertraline resulted in an elevation of 5-HT in serum and platelets, presumably by inhibiting SERT, and therefore lead to a better treatment of MI with comorbid depression.
Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The sertraline anti Depressant heart attack randomized trial (SADHART) platelet substudy.
Adicionalmente, un seguimiento llevado a cabo cinco anos despues a los pacientes que participaron en el SADHART, evidencio que al comparar aquellos que habian tenido la remision de los sintomas presentaban una menor cantidad de eventos cardiovasculares en el tiempo frente a aquellos que no habian alcanzado la remision (Jiang et al., 2011).
El SADHART (Jiang et al., 2011; Jiang et al., 2008), el ENRICHD (Berkman et al., 2003; Carney et al., 2004) y el Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) (Lesperance et al., 2007; van Zyl et al., 2009) son algunos de los estudios mas reconocidos en este campo.
Glassman served as a member of the steering committee for SADHART. He also has been a consultant for and has received honoraria from Pfizer Inc., which markets sertraline and provided partial support for the study.
Glassman was a member of the steering committee for SADHART and has been a consultant for Pfizer, which markets sertraline (Zoloft).
The patients selected for SADHART were not seeking psychiatric treatment and, as a result, the sample had much milder depression and depressive episodes that were shorter than would normally be expected in a typical drug trial.
The SADHART findings offer "the first real evidence that at least one of the SSRI antidepressants, sertraline, is safe" and efficacious in patients with acute coronary syndromes.
SADHART randomized 369 patients with recent myocardial infarction or unstable angina who met criteria for major depressive disorder to receive 24 weeks of the selective serotonin reuptake inhibitor sertraline or placebo.
But, as in SADHART, there were no meaningful differences in any cardiovascular end points or clinical outcomes regardless of whether antidepressants were used.
But, as in the SADHART study, there were no meaningful differences in any cardiovascular end points or clinical outcomes regardless of whether antidepressants were used.
"But if you look at the SADHART placebo group, only 50% got better while the other 50% did not.